Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease: A Randomized, Placebo-controlled, Double-blinded, Parallel 2-arm, Multi-centre Pilot Trial
Latest Information Update: 03 Jun 2024
At a glance
- Drugs Liposomal GM1-InnoMedica (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors InnoMedica
Most Recent Events
- 03 Jun 2024 New trial record